The No Surprises Act protected patients from surprise bills, but its Independent Dispute Resolution process has become controversial as insurers accuse some providers of exploiting it at scale. The post Is It Time to Change the Independent Dispute Resolution Process of the No Surprises Act? appeared first on MedCity News.
At a time when 98 million prescriptions are abandoned due to cost surprises, it’s critical that all four categories of prescription drug prices are available so consumers can determine how to obtain needed medications at the lowest cost. The post Medication Affordability Depends on Total Price Transparency appeared first on MedCity News.
When paired with the expertise of health care providers, who serve as guides, partners in care, and healers, we have the critical elements in the formula for providing the patient with quality, personalized care, not merely on an episodic basis, but as the foundation of improved whole person care to take them through their life’s…
Tests of two Regenxbio gene therapies have been placed under an FDA clinical hold after a patient in one of the studies developed cancer. Our recap of recent regulatory news also includes one clinical hold removed, several complete response letters, and drug approvals in the U.S. and Europe. The post Clinical Trial Holds Cast Doubt…
January has seen a slew of executive hires, promotions and layoffs across the healthcare industry. For instance, Aidoc, Suki and Particle Health named new executives. There were also layoffs at organizations including Takeda, Trinity Health and Horizon BCBS New Jersey. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on…
Health tech companies made several major funding announcements in January. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in January appeared first on MedCity News.
More than two years since the official end of the covid pandemic, a growing body of research continues to reveal information about the virus and its ability to cause harm long after initial infections resolve. The findings raise fresh concerns about the Trump administration’s decision to reduce recommendations about who should get covid vaccines and…
Lydia Romero se esforzaba por escuchar la voz débil de su esposo al teléfono. Una semana antes, agentes de inmigración apresaron a Julio César Peña delante de su casa en Glendale, California, y se lo llevaron. Ahora estaba en un hospital, después de haber sufrido un mini derrame cerebral. Le dijo a Romero que lo…
AstraZeneca’s deal with CSPC Pharmaceutical Group includes a Phase 1-ready obesity drug that hits the same targets as Eli Lilly’s obesity drug Zepbound, but with monthly dosing. The new collaboration builds on an existing drug R&D relationship between the two companies. The post AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC…
Ahead of the Trump administration’s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicare’s negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMS’s Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being…